sanofi–gsk covid-19 vaccine sanofi–gsk covid-19 vaccine the sanofi–gsk covid-19 vaccine sold under the brand name vidprevtyn beta, is a covid-19 vaccine developed by sanofi pasteur and gsk. sanofi–gsk covid-19 vaccinevaccine descriptiontargetsars-cov-2vaccine typeprotein subunitclinical datatrade namesvidprevtyn betaother namesvat00002, vat00008routes ofadministrationintramuscularatc codej07bx03 (who) legal statuslegal status eu: marketing authorization granted list of covid-19 vaccine authorizations identifiersdrugbankdb16427 part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal the sanofi–gsk covid‑19 vaccine was approved for medical use in the european union in november 2022. medical uses the sanofi–gsk covid‑19 vaccine is used as a booster for active immunisation against sars‑cov‑2 virus in order to prevent covid‑19. pharmacology the sanofi–gsk covid‑19 vaccine is a recombinant protein subunit vaccine containing the sars-cov-2 spike protein, which is produced in insect cells via a baculovirus vector. it also includes an adjuvant made by gsk. it uses the same technology as sanofi's flublok influenza vaccine. history the sanofi–gsk covid‑19 vaccine is under development by the french pharmaceutical company sanofi and the british-american pharmaceutical company glaxosmithkline. advanced clinical trials of the vaccine were delayed in december 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021. clinical trials in september 2020, sanofi-gsk started for phase i trials with 440 participants in the united states. in february 2021, sanofi-gsk started for phase ii trials with 722 participants in the united states. on 27 may 2021, the vaccine began a phase iii trial involving 35,000 participants, which increased to 37,430 participants with trials in colombia, dominican republic, ghana, honduras, india, japan, kenya, mexico, nigeria, pakistan, sri lanka, uganda, and the united states. in september 2021, sanofi-gsk started a booster trial in the united kingdom. in this study, they will enroll up to 3,145 volunteers who have previously completed a covid-19 a full vaccine course between 4 and 10 months previously. the purpose of this study is to determine if the investigational covid-19 vaccines are safe and can stimulate and broaden the immune response against the different covid-19 variants that cause covid-19 when given as a single booster injection in participants who have previously been vaccinated with a full course of an authorized covid-19 vaccine. non-clinical studies during its development, the vaccine was tested in several non-clinical models including mice, hamsters, rabbits and non-human primates. society and culture legal status in july 2021, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) started a rolling review of vidprevtyn, a covid-19 vaccine developed by sanofi pasteur. the chmp's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target sars-cov-2, the virus that causes covid-19, and may help protect against the disease. vidprevtyn beta was approved for medical use in the european union in november 2022. economics in july 2020, the uk government signed up for 60 million doses of a covid-19 vaccine developed by gsk and sanofi. it uses a recombinant protein-based technology from sanofi and gsk's pandemic technology. the companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021. the company also agreed to a $2.1 billion deal with the united states to produce 100 million doses of the vaccine.